<DOC>
	<DOCNO>NCT01081873</DOCNO>
	<brief_summary>Document treatment pattern evaluate LUCRIN / LUCRIN-TRIDEPOTÂ® ( Leuprolide ) alternative therapeutic approach treatment advanced prostate cancer normal clinical practice accordance term Belgian marketing authorization reimbursement condition .</brief_summary>
	<brief_title>Study Document Treatment Patterns Evaluate Leuprolide Alternative Therapeutic Approaches Treatments Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Patients advanced prostate cancer prescribe Lucrin/ LucrinTridepot treatment local reimbursement guideline ; Patients willing consent data collect provided Abbott Laboratories . Contraindications accord Summary Product Characteristics ( SPC ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Multicenter study</keyword>
</DOC>